After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Eli Lilly (LLY) was upgraded to 'buy' from 'neutral' on Tuesday at Goldman Sachs.
Goldman Sachs upped Eli Lilly's (LLY) stock rating to 'buy' this morning, citing its solid pipeline.
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.